CX Institutional Has $1.61 Million Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX)

CX Institutional grew its position in Quest Diagnostics Incorporated (NYSE:DGX) by 5.5% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 10,338 shares of the medical research company’s stock after acquiring an additional 537 shares during the period. CX Institutional’s holdings in Quest Diagnostics were worth $1,605,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in DGX. Integrated Advisors Network LLC grew its holdings in shares of Quest Diagnostics by 13.6% in the 4th quarter. Integrated Advisors Network LLC now owns 2,157 shares of the medical research company’s stock valued at $297,000 after buying an additional 259 shares during the period. Wellington Management Group LLP grew its holdings in shares of Quest Diagnostics by 0.7% in the 4th quarter. Wellington Management Group LLP now owns 2,632,326 shares of the medical research company’s stock valued at $362,945,000 after buying an additional 18,533 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Quest Diagnostics by 7.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 45,711 shares of the medical research company’s stock valued at $6,303,000 after buying an additional 3,049 shares during the period. HighPoint Advisor Group LLC acquired a new position in shares of Quest Diagnostics in the 4th quarter valued at $585,000. Finally, CWM LLC grew its holdings in shares of Quest Diagnostics by 4.9% in the 1st quarter. CWM LLC now owns 19,097 shares of the medical research company’s stock valued at $2,542,000 after buying an additional 897 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Insider Activity

In other news, SVP Mark E. Delaney sold 420 shares of the company’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total value of $60,093.60. Following the sale, the senior vice president now directly owns 5,019 shares of the company’s stock, valued at approximately $718,118.52. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Mark E. Delaney sold 420 shares of the company’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total value of $60,093.60. Following the sale, the senior vice president now directly owns 5,019 shares of the company’s stock, valued at approximately $718,118.52. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Karthik Kuppusamy sold 1,990 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total transaction of $304,987.40. Following the completion of the sale, the senior vice president now directly owns 11,459 shares in the company, valued at approximately $1,756,206.34. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.79% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DGX. Barclays boosted their price target on shares of Quest Diagnostics from $144.00 to $154.00 and gave the company an “equal weight” rating in a report on Tuesday, August 27th. Evercore ISI began coverage on shares of Quest Diagnostics in a research report on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price objective on the stock. Truist Financial boosted their price objective on shares of Quest Diagnostics from $158.00 to $165.00 and gave the company a “hold” rating in a research report on Monday, October 7th. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Citigroup raised shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $145.00 to $165.00 in a research report on Wednesday, July 10th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $154.92.

Quest Diagnostics Trading Up 0.2 %

Shares of NYSE:DGX opened at $149.35 on Wednesday. The company’s 50-day moving average price is $152.62 and its two-hundred day moving average price is $143.75. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91. Quest Diagnostics Incorporated has a one year low of $120.87 and a one year high of $159.36. The stock has a market capitalization of $16.59 billion, a PE ratio of 20.10, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.31 by $0.04. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.39 billion. During the same period in the previous year, the firm posted $2.30 EPS. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, equities analysts forecast that Quest Diagnostics Incorporated will post 8.89 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be issued a $0.75 dividend. The ex-dividend date is Friday, October 4th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 2.01%. Quest Diagnostics’s payout ratio is 40.38%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.